Inhibitory action of daunorubicin on lipopolysaccharide-stimulated inducible-type nitric oxide synthase induction in alveolar macrophages

Journal of Pharmacological Sciences

Volumn 99, Issue 4, 2005, Pages 364-372

  Saito, Fumiaki ^a   Matsusaka, Satoshi ^a   Kato, Hirohisa ^a   Wakabayashi, Ichiro ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Anthracycline antibiotic; Daunorubicin; Extracellular regulated kinase; Macrophage; Nitric oxide

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; DAUNORUBICIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LUNG ALVEOLUS MACROPHAGE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 29144472266     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0050513     Document Type: Article

References (16)

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
2. Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun. 1988;157:87-94.
3. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323-350.
4. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997;54 Suppl 4:1-7.
5. Sakai T, Muramatsu I, Hayashi N, Ishii Y. Inhibition of NO synthase induction by an anticancer drug 4′-epi-doxorubicin in rats. Gen Pharmacol. 1996;27:1367-1372.
6. Inagaki R, Taniguchi T, Sakai T, Hayashi N, Ishii Y, Muramatsu I. Anticancer drugs inhibit induction of NO synthase in rat in vivo. Gen Pharmacol. 1999;32:185-188.
7. Wakabayashi I, Mayer B, Groschner K. Inhibitory effects of aclarubicin on nitric oxide production in aortic smooth muscle cells and macrophages. Biochem Pharmacol. 2000;59:719-726.
8. Chandler DB, Fulmer JD. Prostaglandin synthesis and release by subpopulations of rat alveolar macrophages. J Immunol. 1987;139:893-898.
9. Chandler DB, Fuller WC, Jackson RM, Fulmer JD. Fractionation of rat alveolar macrophages by isopycnic centrifugation: morphological, cytochemical, biochemical, and functional properties. J Leukoc Biol. 1986;39:371-383.
10. Rao KM. MAP kinase activation in macrophages. J Leukoc Biol. 2001;69:3-10.
11. Yasui K, Suehiro A, Kakishita E, Wakabayashi I. Effects of antitumor agents on inducible prostacyclin production in vascular smooth muscle. Eur J Pharmacol. 1999;376:301-305.
12. Liew FY. Regulation of nitric oxide synthesis in infectious and autoimmune diseases. Immunol Lett. 1994;43:95-98.
13. Marcinkiewicz J, Chain BM. Differential regulation of cytokine production by nitric oxide. Immunology. 1993;80:146-150.
14. Taylor-Robinson AW, Liew FY, Severn A, Xu D, McSorley SJ, Garside P, et al. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol. 1994;24:980-984.
15. Akaike T, Maeda H. Nitric oxide and virus infection. Immunology. 2000;101:300-308.
16. Nathan C. Points of control in inflammation. Nature. 2002;420:846-852.